Newsletter – May 2024 – Opportunities Fund
The MOF closed marginally higher in May. Read more.
READ MORENewsletter – May 2024 – Biotech Fund
Equities returned to winning ways in May following a negative month. Read more.
READ MORENewsletter – April 2024 – Biotech Fund
The equity market stumbled in April with the S&P 500 decreasing by 4.1%, breaking its streak of five consecutive positive months. Read more.
READ MORENewsletter – April 2024 – Opportunities Fund
Are they, aren’t they, they are, they aren’t – Interest Rates. Read more.
READ MORENewsletter – March 2024 – Biotech Fund
The Merchant Biotech Fund retreated a little this month finishing the month at $1.3940. Read more.
READ MORENewsletter – March 2024 – Opportunities Fund
The MOF continued to recover through the month of March. Read more.
READ MORENewsletter – February 2024 – Opportunities Fund
The MOF rebounded slightly in February. Read more.
READ MORENewsletter – February 2024 – Biotech Fund
The month of February was a strong month for the Merchant Biotech Fund (Fund or MBF) finishing up 16.71%. Read more.
READ MORENewsletter – January 2024 – Opportunities Fund
We are starting to see green shoots in our sector of the market of late. Read more.
READ MORENewsletter – January 2024 – Biotech Fund
The Merchant Biotech Fund (MBF or Fund) started the 2024 calendar year well, finishing up 11.12% for the month of January. Read more.
READ MORENewsletter – December 2023 – Biotech Fund
Closing out the year the Merchant Biotech Fund finished up strongly. Read more.
READ MORENewsletter – December 2023 – Opportunities Fund
Pleasingly the Merchant Opportunities Fund rebounded somewhat during the month of December. Read more.
READ MORENewsletter – November 2023 – Biotech Fund
The Merchant Biotech Fund (MBF or Fund) had a strong month in November, finishing at $1.0058. Read more.
READ MORENewsletter – November 2023 – Opportunities Fund
The bright spot at Merchant has been the performance of the Merchant Biotech Fund. Read more.
READ MORENewsletter – September 2023 – Biotech Fund
The general market softened into September and the biotech sector held its ground. Read more.
READ MORENewsletter – September 2023 – Opportunities Fund
Greetings from Munich. I am here at the moment assisting HAPA (EuroCann). Read more.
READ MORENewsletter – July 2023 – Biotech Fund
At the end of July, it appeared the Australian inflation rate was softening with monthly CPI hitting a 16-month low. Read more.
READ MORENewsletter – July 2023 – Opportunities Fund
A quiet month in the markets post June 30th selling in Small-Cap land. Read more.
READ MORENewsletter – June 2023 – Opportunities Fund
The Merchant Opportunities Fund softened in the month of June. Read more.
READ MORENewsletter – June 2023 – Biotech Fund
The Merchant Biotech Fund finished up 43.25% for the financial year. Read more.
READ MORENewsletter – April 2023 – Biotech Fund
The Merchant Biotech Fund (“MBF” or “the Fund”) is up 59% for the financial year vs the ASX Healthcare 300 Index (XHK) up 6.09% over the same period. Read more.
READ MORENewsletter – April 2023 – Opportunities Fund
The overall market was relatively stagnant during the month of April. Read more.
READ MORENewsletter – March 2023 – Biotech Fund
The Merchant Biotech Fund closed up 5.5% for the month. Read more.
READ MORENewsletter – March 2023 – Opportunities Fund
March was a tale of two halves – first half being terrible and second half being less terrible… Read more.
READ MORENewsletter – February 2023 – Biotech Fund
Global equities declined in February after a strong January. Merchant Biotech Fund (MBF or Fund) retreated a little to finish the month $0.7691.Read more.
READ MORENewsletter – February 2023 – Opportunities Fund
The month of February was a tale of two halves – first half of the month being relatively good and second half being relatively bad as the index wobbled across the board as a result of continued increases in global interest rates. Read more.
READ MORENewsletter – January 2023 – Biotech Fund
A solid January could be a good sign for the market and potentially foreshadow a continued uptick in the months that follow. Read more.
READ MORENewsletter – January 2023 – Opportunities Fund
Another relatively benign month for the Merchant Opportunities Fund. Read more.
READ MORENewsletter – December 2022 – Opportunities Fund
The Merchant Opportunities Fund (MOF) is currently up 19.60% net of fees since 30 June 2022. Read more.
READ MORENewsletter – December 2022 – Biotech Fund
The Merchant Biotech Fund (MBF) finished December up 29.34% for the Financial Year. Read more.
READ MORENewsletter – November 2022 – Biotech Fund
November started on a sombre note amid the Fed’s rate hike and better-than-expected job numbers. Read more.
READ MORENewsletter – November 2022 – Opportunities Fund
The ASX continued to tread water in November and settled into the Christmas trading period with a marked drop in liquidity despite an overall bullish trend. Read more.
READ MORENewsletter – October 2022 – Biotech Fund
Global equity markets rounded the month out higher after a brutal September slump. In the US the Dow ended October with a gain of +13.96%, its best monthly advance since January 1976 and its 10th best month of the last century. Read more.
READ MORENewsletter – October 2022 – Opportunities Fund
Apologies for the lateness of this newsletter, I’ve just returned from Frankfurt where we’ve been visiting HAPA Pharm, our German Medical Cannabis holding as it readies to list in the new year. Read more.
READ MORENewsletter – September 2022 – Biotech Fund
This month the bear market intensified, with the S&P 500 joining the Dow Jones in undercutting their June lows and the Nasdaq composite sitting just above that level. Read more.
READ MORENewsletter – September 2022 – Opportunities Fund
The Merchant Opportunities Fund (MOF) had a relatively benign month given the global market swings during September. Read more.
READ MORENewsletter – August 2022 – Biotech Fund
The question we wanted answered in July was “can the rally last?” August provided the answer. Read more.
READ MORENewsletter – August 2022 – Opportunities Fund
The Merchant Opportunities Fund (MOF or Fund) pulled back slightly along with the market during the month of August to be up 18.40% for the Financial Year. Read more.
READ MORENewsletter – July 2022 – Biotech Fund
At the closing bell on the last trading day of the Financial Year, the ASX Biotech Sector was down approximately 40% for the full Financial Year. Read more.
READ MORENewsletter – July 2022 – Opportunities Fund
Well, that was a financial year to forget! Read more.
READ MORENewsletter – May 2022 – Opportunities Fund
The MOF is currently down 15.41% since 30 June against a Small Ordinaries Index that is at the time of writing, down 19.94% for the Financial Year. Read more.
READ MORENewsletter – May 2022 – Biotech Fund
Against the ASX & US Listed Biotech Indexes we are faring better but at the moment it’s all a little painful. Read more.
READ MORENewsletter – April 2022 – Biotech Fund
April brought another volatile month on the stock market. The release of inflation numbers and a rise in interest rates both globally and domestically led to a shakeout. Read more.
READ MORENewsletter – April 2022 – Opportunities Fund
With the Small Ordinaries off 15.36% for the 6 months, the Merchant Opportunities Fund (MOF) over for the financial year is currently down 12.18%. Read more.
READ MORENewsletter – March 2022 – Biotech Fund
As the dust settles on the month of March 2022 for the Merchant Biotech Fund increasing inflation and the Russian war in Ukraine continue to plague the technology/healthcare sector. Read more.
READ MOREOzHarvest – Help Keep The Wheels Turning + Provide Vital Food Relief
I’m helping OzHarvest raise money to feed people in need and I’d love your support. Read more.
READ MORENewsletter – March 2022 – Opportunities Fund
The Merchant Opportunities Fund is currently down 6.25% for the Financial Year having regained some ground to March 31st. Read more.
READ MORENewsletter – February 2022 – Biotech Fund
The Merchant Biotech Fund continued to suffer during February with the Biotechnology and Technology sectors both being hardest hit as a result of the Russian invasion of Ukraine.
READ MORENewsletter – February 2022 – Opportunities Fund
The Merchant Opportunities Fund continued its retracement at the hands of the market gods in February.
READ MORENewsletter – January 2022 – Biotech Fund
Auspiciously January 2022 will go down as the first month investing for the Merchant Biotech Fund.
READ MORE